American Academy of Neurology (AAN) Annual Meeting 2026 | iPharmaCenter

NICE Recommends First Vitiligo Treatment for Use in the NHS

American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2026 | iPharmaCenter

Eli Lilly Launches Multi-Dose Prefilled Pen for Tirzepatide, 2025's Top Weight Management Drug | iPharmaCenter

Novo Nordisk to Slash U.S. List Prices for Semaglutide Portfolio from 2027 Amid Rising Competitive Pressure

Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter

CagriSema misses non‑inferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% | iPharmaCenter

Congress of ECCO 2026: Key Clinical Trial Updates Shaping the Future of IBD Care

Novartis Advances Remibrutinib Toward FDA Approval in Chronic Inducible Urticaria | iPharmaCenter

Lilly's Taltz + Zepbound Combo Achieves Superior Psoriasis Clearance and Weight Loss in Phase 3b Trial | iPharmaCenter

Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter

GSK’s ultra‑long‑acting IL‑5 biologic Exdensur wins EU approval for severe asthma and CRSwNP | iPharmaCenter

Brazil Healthcare System | How Brazil's healthcare work? Funding | How are drugs approved and reimbursed? | iPharmaCenter

The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter

Lilly to Acquire Novel CAR-T Innovator Orna Therapeutics for $2.4 Billion to Advance In Vivo Cell Therapy Platform

EHSF 2026: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa

ACTRIMS 2026: Roche’s investigational therapy fenebrutinib shows breakthrough results in primary progressive multiple sclerosis (PPMS)

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

From $31.60 to $25: How New PBS Rules Make Prescriptions More Affordable

CDSCO Clears Durvalumab with FLOT as New Perioperative Standard for Gastric Cancer Patients in India | iPharmaCenter

GSK’s RSV Vaccine, Arexvy is now approved for all adults in Europe | iPharmaCenter

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

Roche’s GLP‑1/GIP receptor agonist CT‑388 demonstrated strong efficacy in patients with obesity | iPharmaCenter

NHS England lowers FIT threshold to catch more bowel cancers early

NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter

Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter

Sun Pharma obtains DCGI nod to produce generic semaglutide injection for weight management in India | iPharmaCenter

SFDA approved the registration of Anktiva for selected bladder and lung cancer indications | iPharmaCenter

CVS Health outlines strategy to streamline insurance and cut patient costs | iPharmaCenter

FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter

China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter

Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter

Aspect Biosystems Deepens Novo Nordisk Alliance to Advance Curative Cell Therapies for Diabetes | iPharmaCenter

Moderna and Merck report 5‑year follow‑up for intismeran autogene plus pembrolizumab in resected high‑risk melanoma | iPharmaCenter

GSK to Acquire RAPT in $2.2 Billion Deal, Adding Late-Stage Anti-IgE Candidate Ozureprubart for Food Allergy and Chronic Spontaneous Urticaria | iPharmaCenter

EMA Begins Review of Trastuzumab Deruxtecan Plus Pertuzumab as First-Line Therapy for HER2 Positive Metastatic Breast Cancer | iPharmaCenter

Novartis’ ianalumab moves a step closer to approval in Sjögren’s disease with FDA Breakthrough Therapy designation | iPharmaCenter

Germany’s Federal Ministry of Health (BMG) initiated two research funding projects to strengthen women's health | iPharmaCenter

J.P. Morgan 2026 Healthcare Conference | News | Updates | iPharmaCenter

Inside Trump’s Great Healthcare Plan: Drug Prices, Premiums, and Transparency Explained

Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma

American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium 2026 | News | Updates | iPharmaCenter

Top-Selling Drugs of 2026 | iPharmaCenter

Germany Approves Draft Law to Strengthen Local Pharmacies (ApoVWG) | iPharmaCenter

Eli Lilly to acquire Ventyx Biosciences; will significantly strengthen immunology and neurology portfolio | iPharmaCenter

China Grants Approval to Nucala for COPD Management | iPharmaCenter

Japan approves GSK's Exdensur for asthma and chronic rhinosinusitis with nasal polyps

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter

Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases